 | • レポートコード：GIR-2104Z10554 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療・医薬品 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、パーキンソン病治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。パーキンソン病治療薬の種類別市場規模（経口、経皮、皮下、腸内注入）、用途別市場規模（病院、診療所、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・パーキンソン病治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Abbvie、Biogen、Boehringer Ingelheim GmbH、F. Hoffman-La Roche、GlaxoSmithKline、H. Lundbeck A/S、Impax Labs、Newron Pharmaceuticals SpA、Novartis AG、Orion Corporation、Teva Pharmaceutical Industries Ltd.、UCB S.A. ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：経口、経皮、皮下、腸内注入 ・用途別分析2016年-2026年：病院、診療所、その他 ・パーキンソン病治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・パーキンソン病治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・パーキンソン病治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・パーキンソン病治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・パーキンソン病治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Parkinson’s Disease Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Parkinson’s Disease Therapeutics size is estimated to be USD 3008.5 million in 2025 from USD 2405.4 million in 2019, with a change XX% between 2019 and 2020. The global Parkinson’s Disease Therapeutics market size is expected to grow at a CAGR of 5.8% for the next five years.
Market segmentation
Parkinson’s Disease Therapeutics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Oral
Transdermal
Subcutaneous
Intestinal Infusion
Market segment by Application, can be divided into
Hospitals
Clinics
Others
Market segment by players, this report covers
Abbvie
Biogen
Boehringer Ingelheim GmbH
F. Hoffman-La Roche
GlaxoSmithKline
H. Lundbeck A/S
Impax Labs
Newron Pharmaceuticals SpA
Novartis AG
Orion Corporation
Teva Pharmaceutical Industries Ltd.
UCB S.A.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Parkinson’s Disease Therapeutics
1.2 Classification of Parkinson’s Disease Therapeutics by Type
1.2.1 Overview: Global Parkinson’s Disease Therapeutics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Parkinson’s Disease Therapeutics Revenue Market Share by Type in 2020
1.2.3 Oral
1.2.4 Transdermal
1.2.5 Subcutaneous
1.2.6 Intestinal Infusion
1.3 Global Parkinson’s Disease Therapeutics Market by Application
1.3.1 Overview: Global Parkinson’s Disease Therapeutics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Parkinson’s Disease Therapeutics Market Size & Forecast
1.5 Global Parkinson’s Disease Therapeutics Market Size and Forecast by Region
1.5.1 Global Parkinson’s Disease Therapeutics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Parkinson’s Disease Therapeutics Market Size by Region, (2016-2021)
1.5.3 North America Parkinson’s Disease Therapeutics Market Size and Prospect (2016-2026)
1.5.4 Europe Parkinson’s Disease Therapeutics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Parkinson’s Disease Therapeutics Market Size and Prospect (2016-2026)
1.5.6 South America Parkinson’s Disease Therapeutics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Parkinson’s Disease Therapeutics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Parkinson’s Disease Therapeutics Market Drivers
1.6.2 Parkinson’s Disease Therapeutics Market Restraints
1.6.3 Parkinson’s Disease Therapeutics Trends Analysis
2 Company Profiles
2.1 Abbvie
2.1.1 Abbvie Details
2.1.2 Abbvie Major Business
2.1.3 Abbvie Parkinson’s Disease Therapeutics Product and Solutions
2.1.4 Abbvie Parkinson’s Disease Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Abbvie Recent Developments and Future Plans
2.2 Biogen
2.2.1 Biogen Details
2.2.2 Biogen Major Business
2.2.3 Biogen Parkinson’s Disease Therapeutics Product and Solutions
2.2.4 Biogen Parkinson’s Disease Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Biogen Recent Developments and Future Plans
2.3 Boehringer Ingelheim GmbH
2.3.1 Boehringer Ingelheim GmbH Details
2.3.2 Boehringer Ingelheim GmbH Major Business
2.3.3 Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics Product and Solutions
2.3.4 Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Boehringer Ingelheim GmbH Recent Developments and Future Plans
2.4 F. Hoffman-La Roche
2.4.1 F. Hoffman-La Roche Details
2.4.2 F. Hoffman-La Roche Major Business
2.4.3 F. Hoffman-La Roche Parkinson’s Disease Therapeutics Product and Solutions
2.4.4 F. Hoffman-La Roche Parkinson’s Disease Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 F. Hoffman-La Roche Recent Developments and Future Plans
2.5 GlaxoSmithKline
2.5.1 GlaxoSmithKline Details
2.5.2 GlaxoSmithKline Major Business
2.5.3 GlaxoSmithKline Parkinson’s Disease Therapeutics Product and Solutions
2.5.4 GlaxoSmithKline Parkinson’s Disease Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 GlaxoSmithKline Recent Developments and Future Plans
2.6 H. Lundbeck A/S
2.6.1 H. Lundbeck A/S Details
2.6.2 H. Lundbeck A/S Major Business
2.6.3 H. Lundbeck A/S Parkinson’s Disease Therapeutics Product and Solutions
2.6.4 H. Lundbeck A/S Parkinson’s Disease Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 H. Lundbeck A/S Recent Developments and Future Plans
2.7 Impax Labs
2.7.1 Impax Labs Details
2.7.2 Impax Labs Major Business
2.7.3 Impax Labs Parkinson’s Disease Therapeutics Product and Solutions
2.7.4 Impax Labs Parkinson’s Disease Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Impax Labs Recent Developments and Future Plans
2.8 Newron Pharmaceuticals SpA
2.8.1 Newron Pharmaceuticals SpA Details
2.8.2 Newron Pharmaceuticals SpA Major Business
2.8.3 Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics Product and Solutions
2.8.4 Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Newron Pharmaceuticals SpA Recent Developments and Future Plans
2.9 Novartis AG
2.9.1 Novartis AG Details
2.9.2 Novartis AG Major Business
2.9.3 Novartis AG Parkinson’s Disease Therapeutics Product and Solutions
2.9.4 Novartis AG Parkinson’s Disease Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Novartis AG Recent Developments and Future Plans
2.10 Orion Corporation
2.10.1 Orion Corporation Details
2.10.2 Orion Corporation Major Business
2.10.3 Orion Corporation Parkinson’s Disease Therapeutics Product and Solutions
2.10.4 Orion Corporation Parkinson’s Disease Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Orion Corporation Recent Developments and Future Plans
2.11 Teva Pharmaceutical Industries Ltd.
2.11.1 Teva Pharmaceutical Industries Ltd. Details
2.11.2 Teva Pharmaceutical Industries Ltd. Major Business
2.11.3 Teva Pharmaceutical Industries Ltd. Parkinson’s Disease Therapeutics Product and Solutions
2.11.4 Teva Pharmaceutical Industries Ltd. Parkinson’s Disease Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans
2.12 UCB S.A.
2.12.1 UCB S.A. Details
2.12.2 UCB S.A. Major Business
2.12.3 UCB S.A. Parkinson’s Disease Therapeutics Product and Solutions
2.12.4 UCB S.A. Parkinson’s Disease Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 UCB S.A. Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Parkinson’s Disease Therapeutics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Parkinson’s Disease Therapeutics Players Market Share
3.2.2 Top 10 Parkinson’s Disease Therapeutics Players Market Share
3.2.3 Market Competition Trend
3.3 Parkinson’s Disease Therapeutics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Parkinson’s Disease Therapeutics Revenue and Market Share by Type (2016-2021)
4.2 Global Parkinson’s Disease Therapeutics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Parkinson’s Disease Therapeutics Revenue Market Share by Application (2016-2021)
5.2 Parkinson’s Disease Therapeutics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Parkinson’s Disease Therapeutics Revenue by Type (2016-2026)
6.2 North America Parkinson’s Disease Therapeutics Revenue by Application (2016-2026)
6.3 North America Parkinson’s Disease Therapeutics Market Size by Country
6.3.1 North America Parkinson’s Disease Therapeutics Revenue by Country (2016-2026)
6.3.2 United States Parkinson’s Disease Therapeutics Market Size and Forecast (2016-2026)
6.3.3 Canada Parkinson’s Disease Therapeutics Market Size and Forecast (2016-2026)
6.3.4 Mexico Parkinson’s Disease Therapeutics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Parkinson’s Disease Therapeutics Revenue by Type (2016-2026)
7.2 Europe Parkinson’s Disease Therapeutics Revenue by Application (2016-2026)
7.3 Europe Parkinson’s Disease Therapeutics Market Size by Country
7.3.1 Europe Parkinson’s Disease Therapeutics Revenue by Country (2016-2026)
7.3.2 Germany Parkinson’s Disease Therapeutics Market Size and Forecast (2016-2026)
7.3.3 France Parkinson’s Disease Therapeutics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Parkinson’s Disease Therapeutics Market Size and Forecast (2016-2026)
7.3.5 Russia Parkinson’s Disease Therapeutics Market Size and Forecast (2016-2026)
7.3.6 Italy Parkinson’s Disease Therapeutics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Parkinson’s Disease Therapeutics Revenue by Type (2016-2026)
8.2 Asia-Pacific Parkinson’s Disease Therapeutics Revenue by Application (2016-2026)
8.3 Asia-Pacific Parkinson’s Disease Therapeutics Market Size by Region
8.3.1 Asia-Pacific Parkinson’s Disease Therapeutics Revenue by Region (2016-2026)
8.3.2 China Parkinson’s Disease Therapeutics Market Size and Forecast (2016-2026)
8.3.3 Japan Parkinson’s Disease Therapeutics Market Size and Forecast (2016-2026)
8.3.4 South Korea Parkinson’s Disease Therapeutics Market Size and Forecast (2016-2026)
8.3.5 India Parkinson’s Disease Therapeutics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Parkinson’s Disease Therapeutics Market Size and Forecast (2016-2026)
8.3.7 Australia Parkinson’s Disease Therapeutics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Parkinson’s Disease Therapeutics Revenue by Type (2016-2026)
9.2 South America Parkinson’s Disease Therapeutics Revenue by Application (2016-2026)
9.3 South America Parkinson’s Disease Therapeutics Market Size by Country
9.3.1 South America Parkinson’s Disease Therapeutics Revenue by Country (2016-2026)
9.3.2 Brazil Parkinson’s Disease Therapeutics Market Size and Forecast (2016-2026)
9.3.3 Argentina Parkinson’s Disease Therapeutics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Parkinson’s Disease Therapeutics Revenue by Type (2016-2026)
10.2 Middle East & Africa Parkinson’s Disease Therapeutics Revenue by Application (2016-2026)
10.3 Middle East & Africa Parkinson’s Disease Therapeutics Market Size by Country
10.3.1 Middle East & Africa Parkinson’s Disease Therapeutics Revenue by Country (2016-2026)
10.3.2 Turkey Parkinson’s Disease Therapeutics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Parkinson’s Disease Therapeutics Market Size and Forecast (2016-2026)
10.3.4 UAE Parkinson’s Disease Therapeutics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Parkinson’s Disease Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Parkinson’s Disease Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Parkinson’s Disease Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Parkinson’s Disease Therapeutics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Parkinson’s Disease Therapeutics Revenue Market Share by Region (2021-2026)
Table 6. Abbvie Corporate Information, Head Office, and Major Competitors
Table 7. Abbvie Major Business
Table 8. Abbvie Parkinson’s Disease Therapeutics Product and Solutions
Table 9. Abbvie Parkinson’s Disease Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Biogen Corporate Information, Head Office, and Major Competitors
Table 11. Biogen Major Business
Table 12. Biogen Parkinson’s Disease Therapeutics Product and Solutions
Table 13. Biogen Parkinson’s Disease Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Boehringer Ingelheim GmbH Corporate Information, Head Office, and Major Competitors
Table 15. Boehringer Ingelheim GmbH Major Business
Table 16. Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics Product and Solutions
Table 17. Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. F. Hoffman-La Roche Corporate Information, Head Office, and Major Competitors
Table 19. F. Hoffman-La Roche Major Business
Table 20. F. Hoffman-La Roche Parkinson’s Disease Therapeutics Product and Solutions
Table 21. F. Hoffman-La Roche Parkinson’s Disease Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 23. GlaxoSmithKline Major Business
Table 24. GlaxoSmithKline Parkinson’s Disease Therapeutics Product and Solutions
Table 25. GlaxoSmithKline Parkinson’s Disease Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. H. Lundbeck A/S Corporate Information, Head Office, and Major Competitors
Table 27. H. Lundbeck A/S Major Business
Table 28. H. Lundbeck A/S Parkinson’s Disease Therapeutics Product and Solutions
Table 29. H. Lundbeck A/S Parkinson’s Disease Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Impax Labs Corporate Information, Head Office, and Major Competitors
Table 31. Impax Labs Major Business
Table 32. Impax Labs Parkinson’s Disease Therapeutics Product and Solutions
Table 33. Impax Labs Parkinson’s Disease Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Newron Pharmaceuticals SpA Corporate Information, Head Office, and Major Competitors
Table 35. Newron Pharmaceuticals SpA Major Business
Table 36. Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics Product and Solutions
Table 37. Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 39. Novartis AG Major Business
Table 40. Novartis AG Parkinson’s Disease Therapeutics Product and Solutions
Table 41. Novartis AG Parkinson’s Disease Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Orion Corporation Corporate Information, Head Office, and Major Competitors
Table 43. Orion Corporation Major Business
Table 44. Orion Corporation Parkinson’s Disease Therapeutics Product and Solutions
Table 45. Orion Corporation Parkinson’s Disease Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Teva Pharmaceutical Industries Ltd. Corporate Information, Head Office, and Major Competitors
Table 47. Teva Pharmaceutical Industries Ltd. Major Business
Table 48. Teva Pharmaceutical Industries Ltd. Parkinson’s Disease Therapeutics Product and Solutions
Table 49. Teva Pharmaceutical Industries Ltd. Parkinson’s Disease Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. UCB S.A. Corporate Information, Head Office, and Major Competitors
Table 51. UCB S.A. Major Business
Table 52. UCB S.A. Parkinson’s Disease Therapeutics Product and Solutions
Table 53. UCB S.A. Parkinson’s Disease Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Global Parkinson’s Disease Therapeutics Revenue (USD Million) by Players (2019-2021)
Table 55. Global Parkinson’s Disease Therapeutics Revenue Share by Players (2019-2021)
Table 56. Breakdown of Parkinson’s Disease Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 57. Parkinson’s Disease Therapeutics Players Head Office, Products and Services Provided
Table 58. Parkinson’s Disease Therapeutics Mergers & Acquisitions in the Past Five Years
Table 59. Parkinson’s Disease Therapeutics New Entrants and Expansion Plans
Table 60. Global Parkinson’s Disease Therapeutics Revenue (USD Million) by Type (2016-2021)
Table 61. Global Parkinson’s Disease Therapeutics Revenue Share by Type (2016-2021)
Table 62. Global Parkinson’s Disease Therapeutics Revenue Forecast by Type (2021-2026)
Table 63. Global Parkinson’s Disease Therapeutics Revenue by Application (2016-2021)
Table 64. Global Parkinson’s Disease Therapeutics Revenue Forecast by Application (2021-2026)
Table 65. North America Parkinson’s Disease Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 66. North America Parkinson’s Disease Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 67. North America Parkinson’s Disease Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 68. North America Parkinson’s Disease Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 69. North America Parkinson’s Disease Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 70. North America Parkinson’s Disease Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 71. Europe Parkinson’s Disease Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 72. Europe Parkinson’s Disease Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 73. Europe Parkinson’s Disease Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 74. Europe Parkinson’s Disease Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 75. Europe Parkinson’s Disease Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 76. Europe Parkinson’s Disease Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 77. Asia-Pacific Parkinson’s Disease Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 78. Asia-Pacific Parkinson’s Disease Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 79. Asia-Pacific Parkinson’s Disease Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 80. Asia-Pacific Parkinson’s Disease Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 81. Asia-Pacific Parkinson’s Disease Therapeutics Revenue by Region (2016-2021) & (USD Million)
Table 82. Asia-Pacific Parkinson’s Disease Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 83. South America Parkinson’s Disease Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 84. South America Parkinson’s Disease Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 85. South America Parkinson’s Disease Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 86. South America Parkinson’s Disease Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 87. South America Parkinson’s Disease Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 88. South America Parkinson’s Disease Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 89. Middle East & Africa Parkinson’s Disease Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 90. Middle East & Africa Parkinson’s Disease Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 91. Middle East & Africa Parkinson’s Disease Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 92. Middle East & Africa Parkinson’s Disease Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 93. Middle East & Africa Parkinson’s Disease Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 94. Middle East & Africa Parkinson’s Disease Therapeutics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Parkinson’s Disease Therapeutics Picture
Figure 2. Global Parkinson’s Disease Therapeutics Revenue Market Share by Type in 2020
Figure 3. Oral
Figure 4. Transdermal
Figure 5. Subcutaneous
Figure 6. Intestinal Infusion
Figure 7. Parkinson’s Disease Therapeutics Revenue Market Share by Application in 2020
Figure 8. Hospitals Picture
Figure 9. Clinics Picture
Figure 10. Others Picture
Figure 11. Global Parkinson’s Disease Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 12. Global Parkinson’s Disease Therapeutics Revenue and Forecast (2016-2026) & (USD Million)
Figure 13. Global Parkinson’s Disease Therapeutics Revenue Market Share by Region (2016-2026)
Figure 14. Global Parkinson’s Disease Therapeutics Revenue Market Share by Region in 2020
Figure 15. North America Parkinson’s Disease Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Europe Parkinson’s Disease Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Asia-Pacific Parkinson’s Disease Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. South America Parkinson’s Disease Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Parkinson’s Disease Therapeutics Market Drivers
Figure 20. Parkinson’s Disease Therapeutics Market Restraints
Figure 21. Parkinson’s Disease Therapeutics Market Trends
Figure 22. Abbvie Recent Developments and Future Plans
Figure 23. Biogen Recent Developments and Future Plans
Figure 24. Boehringer Ingelheim GmbH Recent Developments and Future Plans
Figure 25. F. Hoffman-La Roche Recent Developments and Future Plans
Figure 26. GlaxoSmithKline Recent Developments and Future Plans
Figure 27. H. Lundbeck A/S Recent Developments and Future Plans
Figure 28. Impax Labs Recent Developments and Future Plans
Figure 29. Newron Pharmaceuticals SpA Recent Developments and Future Plans
Figure 30. Novartis AG Recent Developments and Future Plans
Figure 31. Orion Corporation Recent Developments and Future Plans
Figure 32. Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans
Figure 33. UCB S.A. Recent Developments and Future Plans
Figure 35. Global Parkinson’s Disease Therapeutics Revenue Share by Players in 2020
Figure 36. Parkinson’s Disease Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 37. Global Top 3 Players Parkinson’s Disease Therapeutics Revenue Market Share in 2020
Figure 38. Global Top 10 Players Parkinson’s Disease Therapeutics Revenue Market Share in 2020
Figure 39. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 40. Global Parkinson’s Disease Therapeutics Revenue Share by Type in 2020
Figure 41. Global Parkinson’s Disease Therapeutics Market Share Forecast by Type (2021-2026)
Figure 42. Global Parkinson’s Disease Therapeutics Revenue Share by Application in 2020
Figure 43. Global Parkinson’s Disease Therapeutics Market Share Forecast by Application (2021-2026)
Figure 44. North America Parkinson’s Disease Therapeutics Sales Market Share by Type (2016-2026)
Figure 45. North America Parkinson’s Disease Therapeutics Sales Market Share by Application (2016-2026)
Figure 46. North America Parkinson’s Disease Therapeutics Revenue Market Share by Country (2016-2026)
Figure 47. United States Parkinson’s Disease Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Canada Parkinson’s Disease Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Mexico Parkinson’s Disease Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Europe Parkinson’s Disease Therapeutics Sales Market Share by Type (2016-2026)
Figure 51. Europe Parkinson’s Disease Therapeutics Sales Market Share by Application (2016-2026)
Figure 52. Europe Parkinson’s Disease Therapeutics Revenue Market Share by Country (2016-2026)
Figure 53. Germany Parkinson’s Disease Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. France Parkinson’s Disease Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. United Kingdom Parkinson’s Disease Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Russia Parkinson’s Disease Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Italy Parkinson’s Disease Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Asia-Pacific Parkinson’s Disease Therapeutics Sales Market Share by Type (2016-2026)
Figure 59. Asia-Pacific Parkinson’s Disease Therapeutics Sales Market Share by Application (2016-2026)
Figure 60. Asia-Pacific Parkinson’s Disease Therapeutics Revenue Market Share by Region (2016-2026)
Figure 61. China Parkinson’s Disease Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Japan Parkinson’s Disease Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. South Korea Parkinson’s Disease Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. India Parkinson’s Disease Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Southeast Asia Parkinson’s Disease Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Australia Parkinson’s Disease Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. South America Parkinson’s Disease Therapeutics Sales Market Share by Type (2016-2026)
Figure 68. South America Parkinson’s Disease Therapeutics Sales Market Share by Application (2016-2026)
Figure 69. South America Parkinson’s Disease Therapeutics Revenue Market Share by Country (2016-2026)
Figure 70. Brazil Parkinson’s Disease Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Argentina Parkinson’s Disease Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Middle East and Africa Parkinson’s Disease Therapeutics Sales Market Share by Type (2016-2026)
Figure 73. Middle East and Africa Parkinson’s Disease Therapeutics Sales Market Share by Application (2016-2026)
Figure 74. Middle East and Africa Parkinson’s Disease Therapeutics Revenue Market Share by Country (2016-2026)
Figure 75. Turkey Parkinson’s Disease Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Saudi Arabia Parkinson’s Disease Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. UAE Parkinson’s Disease Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Methodology
Figure 79. Research Process and Data Source
世界のパーキンソン病治療薬市場規模・現状・予測（2021年-2027年） Parkinson's disease is a type of progressive movement disorder, characterized by muscle rigidity, and tremors. Market Analysis and Insights: Global Parkinson’s Disease Therapeutics Market The global Parkinson’s Disease Therapeutics market size is projected to reach US$ 3533.7 million by 2026, from …- 世界のパーキンソン病治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Parkinson Disease Drug Market The global Parkinson Disease Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the repo…
- 世界のサンドホフ病治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Sandhoff Disease Therapeutics Market The global Sandhoff Disease Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integ…
- 世界の非アルコール性脂肪肝疾患治療薬市場規模・現状・予測（2021年-2027年） Nonalcoholic fatty liver disease (NAFLD) is a condition in which excessive fatty accumulation in the hepatocytes. There are two types of NAFLD, namely simple fatty liver and non-alcoholic steatohepatitis. In simple fatty liver, the fat in the liver is very less and there is no inflammation or liver …
- 世界の炎症性腸疾患治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Inflammatory Bowel Disease Therapeutics Market The global Inflammatory Bowel Disease Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis…